Cargando…

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials

Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes of patients with IgD myeloma from UK phase 3 myeloma trials analyzed in 2 grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agbuduwe, Charles, Iqbal, Gulnaz, Cairns, David, Menzies, Tom, Dunn, Janet, Gregory, Walter, Kaiser, Martin, Owen, Roger, Pawlyn, Charlotte, Child, J. Anthony, Davies, Faith, Morgan, Gareth J., Jackson, Graham H., Drayson, Mark T., Basu, Supratik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631630/ https://www.ncbi.nlm.nih.gov/pubmed/35790108 http://dx.doi.org/10.1182/bloodadvances.2022007608

Ejemplares similares

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Anaplastic morphology in IgD multiple myeloma
por: Roldán Galiacho, Verónica, et al.
Publicado: (2023)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

AL Amyloidosis in a Patient with IgD Myeloma
por: Rafik, Hicham, et al.
Publicado: (2020)

IgD myeloma/immunoblastic lymphoma cells expressing cytokeratin.
por: Sewell, H. F., et al.
Publicado: (1986)

IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis
por: Colombo, I., et al.
Publicado: (2010)

Aggressive FLC Escape in a Patient with IgD Myeloma
por: Farges, Cédric, et al.
Publicado: (2015)

Clinical characteristics and survival of patients with IgD multiple myeloma
por: Li, Yi, et al.
Publicado: (2021)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma
por: Wang, Wei, et al.
Publicado: (2018)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

Haematological manifestations of COVID‐19: From cytopenia to coagulopathy
por: Agbuduwe, Charles, et al.
Publicado: (2020)

N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
por: Chen, Jie, et al.
Publicado: (2017)

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
por: Liu, Jin, et al.
Publicado: (2020)

Physiology of IgD. IV. Enhancement of antibody production in mice bearing IgD-secreting plasmacytomas
Publicado: (1984)

IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion
por: Natori, Kazuhiko, et al.
Publicado: (2008)

Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma
por: Kishi, Seiji, et al.
Publicado: (2018)

Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells
Publicado: (1978)

Physiology of IgD. VI. Transfer of the immunoaugmenting effect of IgD with T delta-containing helper cell populations
Publicado: (1985)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
por: Peres, Lauren C., et al.
Publicado: (2022)

More intensive therapy has a better effect for frail parents with multiple myeloma
por: DuMontier, Clark, et al.
Publicado: (2023)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
por: Pisani, Francesco, et al.
Publicado: (2012)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
por: Husnain, Muhammad, et al.
Publicado: (2016)

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
por: Tsushima, Takafumi, et al.
Publicado: (2021)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Physiology of IgD. I. Compensatory phenomena in B lymphocyte activation in mice treated with anti-IgD antibodies
Publicado: (1981)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023)

Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review
por: Chen, Zhongchuan W., et al.
Publicado: (2013)

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
por: Paiva, Bruno, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3n3eqoc4icncc6gr5njbid5lf9